CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSKAccesswire • 02/10/22
dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.Accesswire • 01/13/22
CureVac's (CVAC) CEO Franz-Werner Haas on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/19/21
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business UpdateAccesswire • 11/19/21
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal StudyBenzinga • 11/18/21
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA VaccineAccesswire • 11/18/21
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune ResponseAccesswire • 11/10/21
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA TechnologyAccesswire • 10/12/21
CureVac stops development of its COVID-19 shot, will focus on new COVID-19 vaccine set for 2022Market Watch • 10/12/21